Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis
- PMID: 8651950
- DOI: 10.1016/0006-2952(95)02437-9
Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis
Abstract
In the present study, we evaluated the pharmacokinetics of the chemotherapeutic agent etoposide (ET) under steady-state conditions and examined its extent of distribution into the CNS of conscious animals. An i.v. infusion of 15 mg/kg/hr was administered to nine rats. Each of the nine rats also received the potent multidrug resistance (MDR) modulator cyclosporine (CSA). Upon the addition of CSA, the i.v. treated animals demonstrated a 53% decrease in ET clearance. This decrease resulted in a greater than 2-fold increase in the steady-state concentrations of ET> The corrected brain-blood ratio (BBR (corr)) was 0.36 +/- 0.18 prior to CSA treatment, and although CNS concentrations increased upon the addition of CSA, there was no increase in the BBR(corr) (0.24 +/- 0.10). The present study demonstrates that the increase of ET in the CNS following CSA is a result of a decrease in ET systemic clearance and not an inhibition of ET efflux from the CNS.
Similar articles
-
Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution.J Pharmacol Exp Ther. 1998 Dec;287(3):911-7. J Pharmacol Exp Ther. 1998. PMID: 9864272
-
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.J Clin Oncol. 1992 Oct;10(10):1635-42. doi: 10.1200/JCO.1992.10.10.1635. J Clin Oncol. 1992. PMID: 1403041 Clinical Trial.
-
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.Cancer. 1993 Dec 1;72(11 Suppl):3502-14. doi: 10.1002/1097-0142(19931201)72:11+<3502::aid-cncr2820721618>3.0.co;2-n. Cancer. 1993. PMID: 7902206 Review.
-
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.J Clin Oncol. 1992 Oct;10(10):1624-34. doi: 10.1200/JCO.1992.10.10.1624. J Clin Oncol. 1992. PMID: 1403040 Clinical Trial.
-
Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.Cancer Chemother Pharmacol. 2004 Aug;54(2):153-60. doi: 10.1007/s00280-004-0784-3. Epub 2004 Apr 27. Cancer Chemother Pharmacol. 2004. PMID: 15114410
Cited by
-
GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.Antimicrob Agents Chemother. 2002 Jul;46(7):2284-6. doi: 10.1128/AAC.46.7.2284-2286.2002. Antimicrob Agents Chemother. 2002. PMID: 12069991 Free PMC article.
-
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.J Clin Invest. 2000 Feb;105(3):279-85. doi: 10.1172/JCI8267. J Clin Invest. 2000. PMID: 10675353 Free PMC article.
-
Application of microdialysis in pharmacokinetic studies.Pharm Res. 1997 Mar;14(3):267-88. doi: 10.1023/a:1012081501464. Pharm Res. 1997. PMID: 9098867 Review.
-
CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration.J Vet Med Sci. 2017 Feb 14;79(2):320-327. doi: 10.1292/jvms.16-0315. Epub 2016 Dec 5. J Vet Med Sci. 2017. PMID: 27916761 Free PMC article.
-
The impact of efflux transporters in the brain on the development of drugs for CNS disorders.Clin Pharmacokinet. 2002;41(2):81-92. doi: 10.2165/00003088-200241020-00001. Clin Pharmacokinet. 2002. PMID: 11888329 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources